University Of Oulu

The medical center is at the forefront of pediatric Acute Myeloid Leukemia research, focusing on innovative treatment protocols to enhance survival rates in children and adolescents. The CHIP-AML22 Master protocol is a pivotal study aimed at improving event-free survival (EFS) by exploring the efficacy of adding gemtuzumab ozogamicin (GO) to induction therapy for CD33-positive AML patients.

• Event-Free Survival Improvement
• Induction Therapy Optimization
• Consolidation Therapy Strategies

This research contributes significantly to the development of tailored therapeutic approaches, potentially setting new standards in pediatric AML treatment.

Specializing in maternal and neonatal health, the center conducts critical research on preventing Group G and C Streptococcal infections during childbirth. The study evaluates the effectiveness of intrapartum antibiotic prophylaxis in reducing infection risks for both mothers and newborns.

• Intrapartum Antibiotic Prophylaxis
• Maternal and Neonatal Infection Prevention
• Group G/C Streptococcus Management

This research is instrumental in shaping guidelines for safer childbirth practices, enhancing outcomes for pregnant women and their babies.

The center is a leader in the treatment of Recurrent and Primary Refractory Ewing Sarcoma, focusing on identifying the most effective chemotherapy regimens. The rEECur trial is an international effort to compare systemic anti-cancer therapies, aiming to optimize treatment efficacy, minimize toxicity, and improve patient acceptability.

• Systemic Anti-Cancer Therapy Comparison
• Treatment Efficacy and Toxicity Balance
• Patient-Centric Treatment Approaches

This research is pivotal in advancing therapeutic options for Ewing Sarcoma, offering hope for improved survival and quality of life for affected patients.